Faron Pharmaceuticals - Innovatiivisia lääketieteen ratkaisuja (Osa 2)

What, what, Clark K. just said that the treatment CAUSES the need for transfusions (TD).

In his message:

“Point B mainly communicates that as a combined effect of the disease and the treatment, a temporary need for transfusions developed, which then resolved.”

My advice: focus on the ball, i.e., business development activities, that’s where the next news will come from. Soon.

9 Likes